These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. HIV exposure through contact with body fluids. Prescrire Int; 2012 Apr; 21(126):100-1, 103-5. PubMed ID: 22515138 [TBL] [Abstract][Full Text] [Related]
30. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine. Jørgensen LB; Katzenstein TL; Gerstoft J; Mathiesen LR; Pedersen C; Nielsen C Antivir Ther; 2000 Sep; 5(3):187-94. PubMed ID: 11075938 [TBL] [Abstract][Full Text] [Related]
31. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment. Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418 [TBL] [Abstract][Full Text] [Related]
32. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415 [TBL] [Abstract][Full Text] [Related]
33. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065 [TBL] [Abstract][Full Text] [Related]
34. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G; AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350 [TBL] [Abstract][Full Text] [Related]
35. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101 [TBL] [Abstract][Full Text] [Related]
37. Abacavir for salvage or intensification. Torres G GMHC Treat Issues; 1999 Jan; 13(1):4-5. PubMed ID: 11366111 [TBL] [Abstract][Full Text] [Related]
38. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa. Strehlau R; Shiau S; Arpadi S; Patel F; Pinillos F; Tsai WY; Coovadia A; Abrams E; Kuhn L J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e70-e77. PubMed ID: 29373687 [TBL] [Abstract][Full Text] [Related]
39. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077 [TBL] [Abstract][Full Text] [Related]
40. Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study. Lake JE; Seang S; Kelesidis T; Liao DH; Hodis HN; Stein JH; Currier JS HIV Clin Trials; 2015 Oct; 16(5):197-206. PubMed ID: 26360501 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]